Cargando…
Management of Statin Intolerance in 2018: Still More Questions Than Answers
Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients freq...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/ https://www.ncbi.nlm.nih.gov/pubmed/29318532 http://dx.doi.org/10.1007/s40256-017-0259-7 |
_version_ | 1783324589964656640 |
---|---|
author | Toth, Peter P. Patti, Angelo Maria Giglio, Rosaria Vincenza Nikolic, Dragana Castellino, Giuseppa Rizzo, Manfredi Banach, Maciej |
author_facet | Toth, Peter P. Patti, Angelo Maria Giglio, Rosaria Vincenza Nikolic, Dragana Castellino, Giuseppa Rizzo, Manfredi Banach, Maciej |
author_sort | Toth, Peter P. |
collection | PubMed |
description | Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutraceuticals can be considered. This review focuses on the definition of statin intolerance and on the development of clinical and therapeutic strategies for its management, including emerging alternative therapies. |
format | Online Article Text |
id | pubmed-5960491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59604912018-05-25 Management of Statin Intolerance in 2018: Still More Questions Than Answers Toth, Peter P. Patti, Angelo Maria Giglio, Rosaria Vincenza Nikolic, Dragana Castellino, Giuseppa Rizzo, Manfredi Banach, Maciej Am J Cardiovasc Drugs Review Article Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutraceuticals can be considered. This review focuses on the definition of statin intolerance and on the development of clinical and therapeutic strategies for its management, including emerging alternative therapies. Springer International Publishing 2018-01-09 2018 /pmc/articles/PMC5960491/ /pubmed/29318532 http://dx.doi.org/10.1007/s40256-017-0259-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Toth, Peter P. Patti, Angelo Maria Giglio, Rosaria Vincenza Nikolic, Dragana Castellino, Giuseppa Rizzo, Manfredi Banach, Maciej Management of Statin Intolerance in 2018: Still More Questions Than Answers |
title | Management of Statin Intolerance in 2018: Still More Questions Than Answers |
title_full | Management of Statin Intolerance in 2018: Still More Questions Than Answers |
title_fullStr | Management of Statin Intolerance in 2018: Still More Questions Than Answers |
title_full_unstemmed | Management of Statin Intolerance in 2018: Still More Questions Than Answers |
title_short | Management of Statin Intolerance in 2018: Still More Questions Than Answers |
title_sort | management of statin intolerance in 2018: still more questions than answers |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/ https://www.ncbi.nlm.nih.gov/pubmed/29318532 http://dx.doi.org/10.1007/s40256-017-0259-7 |
work_keys_str_mv | AT tothpeterp managementofstatinintolerancein2018stillmorequestionsthananswers AT pattiangelomaria managementofstatinintolerancein2018stillmorequestionsthananswers AT gigliorosariavincenza managementofstatinintolerancein2018stillmorequestionsthananswers AT nikolicdragana managementofstatinintolerancein2018stillmorequestionsthananswers AT castellinogiuseppa managementofstatinintolerancein2018stillmorequestionsthananswers AT rizzomanfredi managementofstatinintolerancein2018stillmorequestionsthananswers AT banachmaciej managementofstatinintolerancein2018stillmorequestionsthananswers |